Riken Vitamin Co. Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥34.30 per share, a gain of 20.7% from ¥28.42 per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥758.4 million, a gain of 20.7% from ¥628.4 million in the year-earlier period.
The normalized profit margin rose to 3.3% from 2.8% in the year-earlier period.
Total revenue climbed on an annual basis to ¥22.82 billion from ¥22.39 billion, and total operating expenses totaled ¥21.44 billion, compared with ¥21.37 billion in the prior-year period.
Reported net income increased 38.3% on an annual basis to ¥1.01 billion, or ¥45.90 per share, from ¥734.0 million, or ¥33.19 per share.
For the year, the company's normalized net income totaled ¥132.21 per share, a fall of 10.9% from ¥148.43 per share in the prior year.
Normalized net income was ¥2.92 billion, a decline of 10.9% from ¥3.28 billion in the prior year.
Full-year total revenue totaled ¥85.60 billion, compared with ¥85.42 billion in the prior year, and total operating expenses came to ¥80.95 billion, compared with ¥80.39 billion in the year-earlier period.
The company said reported net income grew 5.7% on an annual basis to ¥3.79 billion, or ¥171.63 per share, in the full year, from ¥3.59 billion, or ¥162.36 per share.
As of June 24, US$1 was equivalent to ¥124.31.